Enrico Opocher

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1668897/publications.pdf

Version: 2024-02-01

21 papers	1,223 citations	759055 12 h-index	996849 15 g-index
22 all docs	22 docs citations	22 times ranked	2806 citing authors

#	Article	IF	Citations
1	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	13.5	596
2	Prognostic factors for progression of childhood optic pathway glioma: A systematic review. European Journal of Cancer, 2006, 42, 1807-1816.	1.3	149
3	Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro-Oncology, 2007, 9, 430-437.	0.6	91
4	Optic pathway glioma: Long-term visual outcome in children without neurofibromatosis type-1. Pediatric Blood and Cancer, 2010, 55, 1083-1088.	0.8	70
5	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 2022, 28, 125-135.	15.2	53
6	SIOP-E-BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low Grade Glioma. Klinische Padiatrie, 2019, 231, 107-135.	0.2	52
7	DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. Cancer Discovery, 2021, 11, 1176-1191.	7.7	46
8	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. Journal of Clinical Oncology, 2021, 39, 2779-2790.	0.8	40
9	Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1. Journal of Neuro-Oncology, 2017, 134, 279-287.	1.4	39
10	NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro-Oncology, 2021, 23, 100-111.	0.6	27
11	Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations. Cancers, 2019, 11, 1790.	1.7	26
12	Correlation of peripapillary retinal nerve fibre layer thickness with visual acuity in paediatric patients affected by optic pathway glioma. Acta Ophthalmologica, 2018, 96, e1004-e1009.	0.6	22
13	A 40-Year Cohort Study of Evolving Hypothalamic Dysfunction in Infants and Young Children (<3) Tj ETQq1 1 0.784314 rgBT /Overloc	1.7	8
14	Regarding â€œNeuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade gliomaâ€• Neuro-Oncology Practice, 2020, 7, 572-573.	1.0	2
15	NFM-04. INITIAL MANAGEMENT STRATEGY AS A DISCRIMINATOR OF VISUAL OUTCOME IN CHILDREN PRESENTING WITH NEUROFIBROMATOSIS TYPE 1 AND OPTIC PATHWAY GLIOMA - RESULTS FROM A SOCIÃ‰TÃ‰ INTERNATIONALE Dâ€™ONCOLOGIE PÃ‰DIATRIQUE EUROPE (SIOPE) CLINICAL TRIALS WORKSHOP. Neuro-Oncology, 2018, 20, i143-i143.	0.6	1
16	LGG-09. A Nationwide Service Evaluation of Safety, Radiologic and Visual Outcome Refining Bevacizumab-based Treatments in Children with Progressive Low-Grade Glioma. Neuro-Oncology, 2022, 24, i89-i89.	0.6	1
17	LG-61DEVELOPING RISK-BASED SELECTION CRITERIA FOR THE NEXT SIOP TRIAL OF â€œSIGHT-SAVING THERAPYâ€• FOR CHILDREN WITH NF1-ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG) - A MULTI-DISCIPLINARY CONSENSUS WORKSHOP. Neuro-Oncology, 2016, 18, iii92.4-iii92.	0.6	0
18	RARE-17. SURVIVAL BENEFIT FOR INDIVIDUALS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME AND BRAIN TUMORS WHO UNDERGO SURVEILLANCE PROTOCOL. A REPORT FROM THE INTERNATIONAL REPLICATION REPAIR CONSORTIUM. Neuro-Oncology, 2020, 22, iii445-iii446.	0.6	0

#	Article	IF	Citations
19	LGG-33. A 40-year cohort study of evolving hypothalamic dysfunction in 90 infants and young children (<3y) with optic pathway gliomas. Neuro-Oncology, 2022, 24, i95-i95.	0.6	0
20	LGG-46. Survival Of The Fittest? A Prognostic Evaluation of Paediatric Low-Grade Glioma (PLGG) Survivor Functional Outcomes. Neuro-Oncology, 2022, 24, i98-i99.	0.6	0
21	LGG-37. Long-term Outcome, Visual Morbidity and Prognostic Factors in Infants and Young Children with Optic Pathway Glioma from the Great Ormond Street Hospital (GOSH) LGG - Cohort. Neuro-Oncology, 2022, 24, i96-i96.	0.6	0